The genome editing is expected to be valued at USD 6.2 billion in 2024. Genome editing is projected to grow at a moderate CAGR of 15.7% from 2024 to 2034. The global genome editing market size is predicted to reach USD 26.5 billion by 2034.
| Attributes | Key Insights |
|---|---|
| Estimated Market Size in 2024 | USD 6.2 billion |
| Projected Market Value in 2034 | USD 26.5 billion |
| Value-based CAGR from 2024 to 2034 | 15.7% |
Exclusive Offer: 30% Off on Regional Reports
Get a free sample report and customize your regions for a 30% discount on your regional report!
Genome editing accounted for 18.4% CAGR from 2019 to 2023. Genome editing tools continue to advance in their delivery methods. The efficiency and safety of CRISPR editing were being improved by developing new and improved methods of delivering CRISPR components to target cells.
Personalized and targeted gene therapies for cancer are being explored using genome editing. Cancer cells can be targeted and destroyed by immune cells that have been enhanced to target and destroy them by scientists.
A growing emphasis was placed on public awareness and engagement as genome editing technologies gained traction. In addition to exploring the potential benefits and risks of gene editing, there was also a conversation about the ethical implications. A 15.7% CAGR is forecast between 2024 and 2034.
| Historical CAGR from 2019 to 2023 | 18.4% |
|---|---|
| Forecast CAGR from 2024 to 2034 | 15.7% |
Check Free Sample Report & Save 40%!
Select your niche segments and personalize your insights for smart savings. Cut costs now!
According to the table provided, South Korea and the United Kingdom have the highest gene editing market revenue. As genome editing technology develops, it will significantly impact the future of the market.
Biological parts, devices, and systems can be designed and constructed through synthetic biology. This technology enables the development of new gene-editing methods and tools, expanding the application possibilities of genome editing.
Gene-editing tools can be delivered to target cells with increased precision using nanotechnology. Genome editing can be more efficient and safer by engineered nanoparticles that carry gene-editing components.
| Countries | Forecast CAGRs from 2024 to 2034 |
|---|---|
| The United States | 15.9% |
| China | 16.2% |
| Japan | 16.5% |
| South Korea | 17.8% |
| The United Kingdom | 17.1% |
A high demand for genome editing is expected in the United States. A CAGR of 15.9% is forecast for the market during the period. Regulatory scrutiny of genome editing technologies, particularly those that may be applied to human therapeutic applications, has been conducted by agencies such as the Food and Drug Administration (FDA).
The United States witnessed several ongoing ethical debates, especially regarding the use of germline editing, as well as the use of genome editing in humans. Technology advancements and an expanding hospital infrastructure are expected to increase the demand for genome editing in the United States.
China is predicted to have a growing market for genome editing. The growth rate is expected to be 16.2% between 2024 and 2034. The market is expected to reach USD 4.2 billion by 2034. The government has contributed significantly to genome editing research and biotech development, fostering innovation and accelerating technology development.
China has dominated research and development in genome editing. Regulations have been implemented to regulate gene editing in humans, though concerns remain about regulating private ventures. A call for stricter regulations and international cooperation has arisen in response to ethical concerns regarding gene editing.
Japan is expected to lead the market for genome editing market. A 16.5% CAGR is predicted for the market during the forecast period. By 2034, the market is expected to generate USD 2.8 billion in revenues. Biotechnology is one of Japan's most advanced fields. Several technological advances have contributed to the growth of genome editing in Japan.
Age-related diseases are among the top medical innovations in Japan, which is one of the world's most rapidly aging populations. A growing interest in genome editing in Japan is driven by its potential to develop personalized treatments for diseases caused by aging.
Research and development in genome editing has been a major focus of South Korea, contributing significantly to the field. A market growth of USD 1.6 billion is anticipated by 2034. South Korea has conducted extensive research into genome editing. Using CRISPR-Cas9 gene scissors and other gene-editing technologies, the country has been actively involved in developing and applying gene-editing technologies.
Several biotech companies in South Korea specialize in genome editing technologies. The products or services provided by some companies include new therapies, gene editing, and agricultural applications. The biotechnology industry in South Korea is highly competitive, and it places great importance on research and development. South Korea invests heavily in cutting-edge technologies that promote growth and innovation as part of its initiatives to maintain its competitiveness globally.
Many renowned universities and research institutions throughout the United Kingdom are actively involved in genome editing research. Research from these institutions is often relevant to medicine and agriculture and contributes to the advancement of the field.
The regulatory environment heavily influences genome editing market dynamics in the United Kingdom. A policy to balance ethical and safety considerations with innovation is being developed in the United Kingdom with respect to genome editing regulations. The United Kingdom is actively researching genetic disorders and clinical trials using genome editing techniques.
A CAGR of 17.1% is projected for the United Kingdom between 2024 and 2034. Government initiatives, private investors, and international collaborations have all invested in and funded the genome editing industry in the United Kingdom.
This section illustrates the market's leading segment. Based on the technology, the meganucleases segment is expected to expand at a CAGR of 15.6% by 2034. Based on the delivery, the ex-vivo segment is expected to expand at a CAGR of 15.3% by 2034.
| Category | CAGR from 2024 to 2034 |
|---|---|
| Meganucleases | 15.6% |
| Ex-vivo | 15.3% |
A meganuclease's ability to recognize and cut specific DNA sequences is highly precise. By 2034, the meganucleas sector is forecasted to record a CAGR of 15.6%. As a result of their specificity, they can be used for targeted genome editing with minimal off-target effects.
Genome editing and repair can be achieved with meganuclease by inducing homologous recombination. Inactivation of specific genes can be achieved using meganuclease’s that cut and target DNA sequences. For example, CCR5, an important HIV receptor, has been targeted by meganuclease in clinical trials.
Ex CRISPR-Cas9, zinc finger nucleases (ZFNs), or transcription activator-like effector nucleases (TALENs) are among the tools that can be introduced into cells for vivo genome editing. Infecting cells with viruses, electroporation, and lipids can all be accomplished this way, with a variety of techniques available for each.
The ex-vivo market is predicted to expand at a CAGR of 15.3% through 2034. In addition to treating genetic disorders and cancer, ex vivo genome editing is also effective against certain viral infections. Mutations in DNA may be corrected, immune response enhanced, or therapeutic genes may be introduced by altering the genetic material of cells.
The manufacturers of genome editing tools are seeking strategic partnerships and collaborations with other companies to expand their research capabilities. Research and development activities by several market players are leading to innovations in genetic testing.
Key Market Developments
| Attributes | Details |
|---|---|
| Estimated Market Size in 2024 | USD 6.2 billion |
| Projected Market Valuation in 2034 | USD 26.5 billion |
| Value-based CAGR 2024 to 2034 | 15.7% |
| Forecast Period | 2024 to 2034 |
| Historical Data Available for | 2019 to 2023 |
| Market Analysis | Value in USD billion |
| Key Regions Covered | North America; Latin America; Western Europe; Eastern Europe; South Asia and Pacific; East Asia; The Middle East and Africa |
| Key Market Segments Covered | Technology, Delivery, Mode, End Use, Application, Region |
| Key Countries Profiled | The United States, Canada, Brazil, Mexico, Germany, The United Kingdom, France, Spain, Italy, Poland, Russia, Czech Republic, Romania, India, Bangladesh, Australia, New Zealand, China, Japan, South Korea, GCC countries, South Africa, Israel |
| Key Companies Profiled | Merck KGaA; Cibus; Recombinetics Inc.; Sangamo; Editas Medicine; Precision Biosciences; CRISPR Therapeutics; Intellia Therapeutics Inc.; Caribou Biosciences Inc.; Cellectis S.A.; AstraZeneca; Takara Bio USA |
As of 2024, the genome editing market is expected to be valued at USD 6.2 billion.
By 2034, the market value of genome editing is expected to reach USD 26.5 billion.
From 2024 to 2034, genome editing is expected to flourish at a CAGR of 15.7%
The meganucleases segment is expected to increase at 15.6% CAGR by 2034.
South Korea is expected to hold the largest market, with a CAGR of 17.8%.
| Estimated Industry Valuation For 2024 | USD 2.9 million |
|---|---|
| Projected Industry Valuation By 2034 | USD 6.5 million |
| Value-based CAGR (2024 to 2034) | 8.1% |
| Market Value (2022) | USD 28.5 Billion |
|---|---|
| Market Value (2032) | USD 170.5 Billion |
| Market CAGR (2022 to 2032) | 19.8% |
| Market Size (2022) | USD 1,545.5 Million |
|---|---|
| Market Size (2032) | USD 4,468 Million |
| Market CAGR (2022 to 2032) | 10.1% |
Explore Life Science & Biotechnology Insights
View Reports
Genome Editing Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
